missing translation for 'onlineSavingsMsg'
Learn More
  1. Home
  2. Products
  3. Antibodies
  4. Primary Antibodies
  5. All Primary Antibodies
  6. 18740213

CD4 Antibody (CE9.1 (Clenoliximab)), DyLight 350 - Chimeric, Novus Biologicals™

Rabbit Monoclonal Antibody

Brand:  Novus Biologicals NBP2-52681UV

Product Code. 18740213

  • € 620.00 / 0.10mL

Please to purchase this item. Need a web account? Register with us today!

This item is not returnable. View return policy

Description

Description

CD4 Monoclonal antibody specifically detects CD4 in Human, Chimpanzee samples. It is validated for Western Blot, Flow Cytometry, ELISA, Immunohistochemistry, Surface Plasmon Resonance, CyTOF, Neutralization
TRUSTED_SUSTAINABILITY
Specifications

Specifications

CD4
Monoclonal
DyLight 350
CD_antigen: CD4, CD4, CD4 antigen, CD4 antigen (p55), CD4 molecule, CD4 receptor, CD4mut, T-cell surface antigen T4/Leu-3, T-cell surface glycoprotein CD4
Domain 1 of human CD4.
0.1 mL
Adaptive Immunity, Cell Biology, Cellular Markers, Cytokine Research, Immunology, Innate Immunity, Regulatory Immunology, Signal Transduction, Stem Cell Markers
920
Store at 4°C in the dark.
IgG λ
Western Blot, Flow Cytometry, ELISA, Immunohistochemistry, Surface Plasmon Resonance
CE9.1 (Clenoliximab)
50 mM Sodium Borate
Rabbit
Protein A purified
RUO
Primary
Human, Chimpanzee
Purified
Product Suggestions

Product Suggestions

Videos
SDS
Documents

Documents

Certificates
Promotions

Promotions

Product Content Correction

Your input is important to us. Please complete this form to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Thank You! Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.